EHMT2 and cancer: they can act on cancer cells to ICD and enhance release/exposure of antigens including neoantigens, to activate DCs and subsequently T cells, with tumor ICD induction and/or enhancing tumor immunogenicity demonstrated for a long list of DNMTi, HDACi and a few HMTi (e.g., EZH2i GSK126 and EPZ6438; G9a/DNMT dual inhibitor CM-272) [114–116, 259].